DK1392347T3 - Fremgangsmåde til at forhindre celledöd med anvendelse af segmenter af neurale trådproteiner - Google Patents

Fremgangsmåde til at forhindre celledöd med anvendelse af segmenter af neurale trådproteiner

Info

Publication number
DK1392347T3
DK1392347T3 DK02729699T DK02729699T DK1392347T3 DK 1392347 T3 DK1392347 T3 DK 1392347T3 DK 02729699 T DK02729699 T DK 02729699T DK 02729699 T DK02729699 T DK 02729699T DK 1392347 T3 DK1392347 T3 DK 1392347T3
Authority
DK
Denmark
Prior art keywords
cell death
proteins
segments
preventing cell
tissue
Prior art date
Application number
DK02729699T
Other languages
English (en)
Inventor
Paul A Averback
Original Assignee
Nymox Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nymox Corp filed Critical Nymox Corp
Application granted granted Critical
Publication of DK1392347T3 publication Critical patent/DK1392347T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK02729699T 2001-05-16 2002-05-16 Fremgangsmåde til at forhindre celledöd med anvendelse af segmenter af neurale trådproteiner DK1392347T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US29097101P 2001-05-16 2001-05-16

Publications (1)

Publication Number Publication Date
DK1392347T3 true DK1392347T3 (da) 2005-12-12

Family

ID=23118262

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02729699T DK1392347T3 (da) 2001-05-16 2002-05-16 Fremgangsmåde til at forhindre celledöd med anvendelse af segmenter af neurale trådproteiner

Country Status (13)

Country Link
US (1) US7572450B2 (da)
EP (1) EP1392347B1 (da)
JP (1) JP2004529179A (da)
KR (1) KR20040008177A (da)
CN (1) CN1558770A (da)
AT (2) ATE300951T1 (da)
BR (1) BR0209630A (da)
CA (1) CA2446945A1 (da)
DE (2) DE60224231D1 (da)
DK (1) DK1392347T3 (da)
ES (1) ES2247329T3 (da)
HK (1) HK1060851A1 (da)
WO (1) WO2002092115A2 (da)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7259232B1 (en) * 2000-10-27 2007-08-21 Nymox Pharmaceutical Corporation Preferred segments of neural thread protein
NZ529911A (en) * 2001-05-25 2008-05-30 Nymox Corp Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
US7317077B2 (en) * 2001-11-16 2008-01-08 Nymox Pharmaceutical Corporation Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
US7544771B2 (en) * 2005-02-23 2009-06-09 Nymox Corporation Protein and its use in diagnosing Alzheimer's disease
US20160361380A1 (en) * 2015-06-12 2016-12-15 Nymox Corporation Combination compositions for treating disorders requiring removal or destruction of unwanted cellular proliferations
US11628202B2 (en) * 2015-07-24 2023-04-18 Nymox Corporation Methods of reducing the need for surgery in patients suffering from benign prostatic hyperplasia
US10183058B2 (en) 2016-06-17 2019-01-22 Nymox Corporation Method of preventing or reducing the progression of prostate cancer
US10172910B2 (en) 2016-07-28 2019-01-08 Nymox Corporation Method of preventing or reducing the incidence of acute urinary retention
US10532081B2 (en) 2016-09-07 2020-01-14 Nymox Corporation Method of ameliorating or preventing the worsening or the progression of symptoms of BPH
US10335453B2 (en) 2017-03-01 2019-07-02 Nymox Corporation Compositions and methods for improving sexual function

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5948634A (en) 1988-12-21 1999-09-07 The General Hospital Coporation Neural thread protein gene expression and detection of alzheimer's disease
CA2006332C (en) 1988-12-21 2003-04-08 Suzanne De La Monte Method of detecting neurological disease or dysfunction
DK1564293T3 (da) * 1993-04-20 2009-01-12 Gen Hospital Corp Nervetrådproteingenekspression og detektion af Alzheimers sygdom
CN1300779A (zh) 1999-12-22 2001-06-27 上海博德基因开发有限公司 一种新的多肽－人神经元线蛋白17和编码这种多肽的多核苷酸
CN1300778A (zh) 1999-12-22 2001-06-27 上海博德基因开发有限公司 一种新的多肽－人神经元线蛋白15和编码这种多肽的多核苷酸
US7259232B1 (en) 2000-10-27 2007-08-21 Nymox Pharmaceutical Corporation Preferred segments of neural thread protein
WO2002074323A2 (en) 2001-03-08 2002-09-26 Nymox Pharmaceutical Corporation Using neural thread proteins to treat tumors and other hyperproliferative disorders

Also Published As

Publication number Publication date
ATE381342T1 (de) 2008-01-15
KR20040008177A (ko) 2004-01-28
CA2446945A1 (en) 2002-11-21
DE60205366D1 (de) 2005-09-08
ATE300951T1 (de) 2005-08-15
EP1392347B1 (en) 2005-08-03
ES2247329T3 (es) 2006-03-01
DE60205366T2 (de) 2006-05-24
DE60224231D1 (de) 2008-01-31
BR0209630A (pt) 2004-03-30
WO2002092115A3 (en) 2003-05-15
US7572450B2 (en) 2009-08-11
CN1558770A (zh) 2004-12-29
WO2002092115A2 (en) 2002-11-21
US20030004107A1 (en) 2003-01-02
HK1060851A1 (en) 2004-08-27
EP1392347A2 (en) 2004-03-03
JP2004529179A (ja) 2004-09-24

Similar Documents

Publication Publication Date Title
DK1392347T3 (da) Fremgangsmåde til at forhindre celledöd med anvendelse af segmenter af neurale trådproteiner
BR9903571A (pt) Método para inibição de glicogênio fosforilase humano
ATE266000T1 (de) Hydroxamsäure- und carbonsäure-derivate mit mmp und tnf hemmender wirkung
ATE303162T1 (de) Natrium kanalblocker zusammensetzungen und deren verwendung
DE60143520D1 (de) Inhibitoren der histon-deacetylase
BR0304648A (pt) Combinação de inibidores de ciclooxigenase-2 e talidomida para o tratamento de neoplasia
ATE297731T1 (de) Metall chelatoren zur verwendung in der behandlung von alzheimers erkrankung mit clioquinol
BRPI0407195A (pt) inibidor de histona desacetilase, composição, e, método para inibir histona desacetilase em uma célula
EA200401341A1 (ru) Применение остеопротегерина для лечения и/или профилактики фиброзного заболевания
ATE329622T1 (de) Steigerung der antikörper-zytokin- fusionsproteinmediierten immunantwort durch mitverabreichung mit einem angiogeneseinhibitor
DK2009025T3 (da) Fremgangsmåde til hæmning af osteoklast-aktivitet
ATE554169T1 (de) Smad7-inhibitoren zur behandlung von krankheiten des zns
BRPI0600195A (pt) composição aquosa
DK0752813T3 (da) Hæmmere af metozoan-parasit-proteaser
DE60327557D1 (de) Verwendung von spongosin (2-methoxyadenosin) zur behandlung von schmerzen, insbesondere hyperalgesie
BRPI0417674A (pt) método para tratar a inflamação aguda em animais, com inibidores de quinase map p38
BR0316163A (pt) Inibidores de histona desacetilase para tratamento de doenças degenerativas do olho
DK1183037T3 (da) Sammensætninger til modulering af immunrespons og til behandling af inflammatoriske sygdomme
EA199900479A1 (ru) Стабилизированные фармацевтические композиции на основе хинупристина и дальфопристина и способ получения
WO2003102148A3 (en) Human prolactin antagonist-angiogenesis inhibitor fusion proteins
ATE250030T1 (de) Peptidverbindungen mit mmp- und tnf-hemmender wirkung
ES2144513T3 (es) Inhibicion de crecimiento tumoral inducido por traumatismo.
DK1121108T3 (da) Ny terapeutisk anvendelse af forbindelser med beta-3-agonistaktivitet
ATE247088T1 (de) Peptidverbindungen mit mmp- und tnf-hemmender wirkung
DE59609977D1 (de) Trapidil zur verwendung in der therapie von immunmodulatorisch beeinflussbaren krankheitsbildern